CN105663715A - Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 - Google Patents
Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 Download PDFInfo
- Publication number
- CN105663715A CN105663715A CN201610088723.0A CN201610088723A CN105663715A CN 105663715 A CN105663715 A CN 105663715A CN 201610088723 A CN201610088723 A CN 201610088723A CN 105663715 A CN105663715 A CN 105663715A
- Authority
- CN
- China
- Prior art keywords
- cough
- green
- preparation
- rhizoma
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, in particular to application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of a medicine for inhibiting the proliferation of astrocytoma cells U251 and a preparation method of the cough and asthma treating Bulbophyllum calodictyon Schlecht tablets. The cough and asthma treating Bulbophyllum calodictyon Schlecht tablets are prepared from medicinal raw materials including 200 g of Bulbophyllum calodictyon Schlecht, 200 g of a Chinese fevervine herb, 100 g of Chinese mahonia stems, 100 g of marsdeniae tenacissimae caulis, 100 g of rhizoma bletillae, 100 g of giant knotweeds, 100 g of garden balsam stems and 100 g of many-flower solomonseal rhizomes and are prepared by adopting supercritical extraction, so that the rheum emodin content is greatly improved.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of green and cough with asthma sheet is in preparation suppression DBT cell U251 cell proliferation application and green and cough with asthma sheet preparation method.
Background technology
Green and cough with asthma particulate level WS-10616(ZD-0616)-2002, it is recorded in country's standard for traditional Chinese medicines compilation internal medicine lung system (two) fascicle. It is made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, there is effect of nourishing YIN and moistening the lung, heat-clearing and toxic substances removing, removing stasis to stop bleeding, for the cough that hot dry criminal's lung causes, hectic fever, the disease such as night sweat.
In prior art, not yet there is the green and cough with asthma sheet report in the application suppressed in people's DBT cell U251 cell proliferation in preparation, also extract preparation aspect there are no green and cough with asthma sheet and adopt the report of supercritical extraction, and traditional water decoction is boiled, the method for alcohol reflux, technique is coarse, backward, and impurity is many, causes that patient's consumption is excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
Goal of the invention: it is an object of the invention to provide a kind of green and that cough with asthma sheet is in preparation suppression DBT cell U251 cell proliferation application.
Further object is that the preparation method that a kind of green and cough with asthma sheet are provided.
It is an object of the invention to by following scheme realization:
Green and cough with asthma sheet suppresses the application in DBT cell U251 cell proliferation in preparation, described green and cough with asthma sheet is made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, described green and cough with asthma sheet preparation method comprises the steps: to take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO2In supercritical extraction device, ethanol is as entrainer, and it is 4-6%, extracting pressure 15-30MPa that entrainer accounts for the percent by volume of total extractant, temperature 30-50 DEG C, CO2Flow l-3ml/g crude drug min, extraction time 700-800min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
Preferably, above-mentioned green and cough with asthma sheet suppresses the application in DBT cell U251 cell proliferation in preparation, described green and cough with asthma sheet preparation method comprises the steps: to take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO2In supercritical extraction device, ethanol is as entrainer, and it is 5% that entrainer accounts for the percent by volume of total extractant, extracting pressure 25MPa, temperature 40 DEG C, CO2Flow 2ml/g crude drug min, extraction time 750min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
In prior art, green and cough with asthma particulate oral, a 10g, 3-4 time on the one. Green and cough with asthma granule dosage is big. Green and the every tablet weight 0.50g of cough with asthma sheet adopting the inventive method to prepare, only needs 2 every time, within 1st, takes 3-4 time. Dose is greatly reduced when having more active component. This conclusion can pass through following it have been experienced that.
The comparison of emodin content in green and cough with asthma sheet prepared by test one, distinct methods
L, instrument and the reagent present invention be green and cough with asthma sheet: prepares by embodiment 1 method, uses 1000g crude drug, extracted makes 200, every tablet weight 0.50g. Former green and cough with asthma granule, according to WS-10616(ZD-0616) prepared by-2002 standard methods. Agilent1200 high performance liquid chromatograph; METTLERAE240 electronic analytical balance; Rheum emodin reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
Measure according to high performance liquid chromatography (Chinese Pharmacopoeia the 4th note on the use 15 of version in 2015).
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Methanol-0.1% phosphoric acid solution (80: 20) is mobile phase; Detection wavelength is 437nm. Number of theoretical plate calculates by rheum emodin peak should be not less than 4000.
It is appropriate that the preparation precision of reference substance solution weighs rheum emodin reference substance, adds methanol and makes every 1ml solution containing 10 μ g, to obtain final product.
The preparation of need testing solution takes that the present invention is green and cough with asthma sheet 10, finely ground, mixing, taking 0.1g, accurately weighed, the 20ml that adds water makes dissolving, add hydrochloric acid 2ml, shake up, be heated to reflux 30 minutes, cooling, adds chloroform 30ml, supersound process 10 minutes, proceed in separatory funnel, dividing and take chloroform solution, water liquid extracts 2 times with chloroform jolting again, each 15ml, combined chloroform liquid, being evaporated in 80 DEG C of water-baths, residue methanol dissolves and is transferred in 10ml measuring bottle, adds methanol dilution to scale, shake up, filter with microporous filter membrane (0.45 μm), take filtrate, to obtain final product.
The preparation of reference product need testing solution takes the green of comparison and cough with asthma granule 20g, finely ground, mixing, take 1g, accurately weighed, the 20ml that adds water makes dissolving, add hydrochloric acid 2ml, shake up, it is heated to reflux 30 minutes, cooling, add chloroform 30ml, supersound process 10 minutes, proceed in separatory funnel, divide and take chloroform solution, water liquid extracts 2 times with chloroform jolting again, each 15ml, combined chloroform liquid, 80 DEG C of water-baths are evaporated, residue methanol dissolves and is transferred in 10ml measuring bottle, add methanol dilution to scale, shake up, filter with microporous filter membrane (0.45 μm), take filtrate, obtain.
Algoscopy precision respectively draws reference substance solution and need testing solution, each 20 μ l of reference product need testing solution, injects chromatograph of liquid, measures, to obtain final product.
3, result
It is shown that the present invention is green and in cough with asthma sheet, the content of rheum emodin is 1.65-3.28mg/ sheet; And the content of rheum emodin is 1.62mg/ bag (every bag containing granule 10g) in former green and cough with asthma granule, each serving 2-4 times that emodin content is former granule 10g content of consumption 2, when dose reduces, emodin content improves a lot.
The studies above shows, adopts green and cough with asthma sheet prepared by preparation method of the present invention, and active constituent content is significantly larger than WS-10616(ZD-0616) the green and cough with asthma granule prepared of method recorded of-2002 standards.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art knows more about the present invention, but this should not being interpreted as, the scope of the above-mentioned theme of the present invention is only limitted to Examples below, and all technology realized based on foregoing of the present invention belong to the scope of the present invention.
Embodiment 1
Take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO2In supercritical extraction device, ethanol is as entrainer, and it is 5% that entrainer accounts for the percent by volume of total extractant, extracting pressure 25MPa, temperature 40 DEG C, CO2Flow 2ml/g crude drug min, extraction time 750min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
After testing, in finished product, the content of rheum emodin is 3.28mg/ sheet.
Embodiment 2
Take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO2In supercritical extraction device, ethanol is as entrainer, and it is 4% that entrainer accounts for the percent by volume of total extractant, extracting pressure 15MPa, temperature 30 DEG C, CO2Flow 1ml/g crude drug min, extraction time 900min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
After testing, in finished product, the content of rheum emodin is 1.65mg/ sheet.
Embodiment 3
Take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, join CO2In supercritical extraction device, ethanol is as entrainer, and it is 6% that entrainer accounts for the percent by volume of total extractant, extracting pressure 30MPa, temperature 60 C, CO2Flow 3ml/g crude drug min, extraction time 800min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
After testing, in finished product, the content of rheum emodin is 2.08mg/ sheet.
Embodiment 4: green and cough with asthma sheet suppresses the experimentation data of people's DBT cell U251 cell proliferation
1. experiment material
1.1 experiment cell strains
People's DBT cell U251 cell, Shandong University's laboratory cell storehouse, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: the present invention is green and cough with asthma sheet: prepare by embodiment 1 method.
Medicinal liquid liquid storage: weigh that 100mg is green and cough with asthma sheet, is dissolved in 5ml dehydrated alcohol, 0.2 μm of frit, 500 μ ldoff pipe subpackages ,-20 DEG C of storages, and 0.2 μm of frit dehydrated alcohol is in order to the use of matched group simultaneously.
1.3 experiment reagents
DMEM (GIBCO company Cat.No.12100-061Lot.No.758137); Hyclone (Tian Hang bio tech ltd, Zhejiang Lot.No.100419); NaHC03(Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin(AMRESCO company); EDTA(AMRESCO company); PenicillinGSodiumSalt(AMRESCO company 1); StreptomycinSulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): PBS(laboratory autogamy);
1.4 experiment equipments
Lycra inverted microscope (Germany Leica model: DMIL); Visible-ultraviolet light microwell plate detector (MD company of U.S. model: SPECTRAMAX190); C02Incubator (FORMA model: 3111); Super-clean bench (safe and sound company of Su Jing group manufactures model: SW-CJ-ZFD);Pure water instrument (Sprlng company of U.S. model: S/N020579); Accurate pipettor (Gilson Inc of France model: P2); Electronic balance (Sai Duolisi company limited of Germany model: BT323S); Full-automatic high-pressure autoclave (SANYO company of Japan model: MLS-3020); Table electrothermal air dry oven (Shanghai precision experimental facilities company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μm of filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) U251 cell DMEM+10%FBS is in 37 DEG C, 5%C02Carry out cellar culture (10cm culture dish), when Growth of Cells to logarithmic (log) phase, collect cell, discard culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 DEG C of digestion 2min, it is added thereto in 5ml complete medium and reaction, is proceeded in centrifuge tube after piping and druming cell, 1000rpm is centrifuged 5min, adjusts concentration of cell suspension 3 × 104Individual/ml.
2) entering in 96 well culture plates by cell kind, every hole adds cell suspension 180 μ l, culture plate put in cell culture incubator (37 DEG C, 5%C02) cellar culture.
3) according to cell growth status, general long to 50%-70%, add green and cough with asthma sheet solution, continue to cultivate 24h.
4) add 20 μ lMTT solution (5mg/ml, i.e. 0.5%MTT) after 24h, continue to cultivate 4h.
5) after 4h, buckle method removes supernatant, pats dry gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, makes crystal fully dissolve. The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument 490nm place.
6) arranging background (being not added with cell, only add culture fluid), control wells (cell, the medicine dissolution medium of same concentrations, culture fluid, MTT, dimethyl sulfoxide), often group sets 6 multiple holes simultaneously.
7) suppression ratio of cell is represented by result with medicine: cell proliferation suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value × 100%. Experiment repeats 3 times.
3. statistical disposition
Adopting the correlation analysis in MicrosoftExcel2007 software and Studentt inspection, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, compare with matched group, when dosage reaches 5mg/ml, to U251 cell inhibitory effect variant (P < 0.05), dosage this difference when 10mg/ml has significance (P < 0.01), has pole significant difference (P < 0.001) when dosage reaches 15-20mg/ml.
Table 1 is green and cough with asthma sheet is to U251 cell inhibitory effect influence research (X ± SD)
| Group | Drug level (mg/ml) | Suppression ratio (%) |
| Matched group | 0 | 0 |
| 1 | 5 | 11.07±5.46 |
| 2 | 10 | 22.01±7.98* |
| 3 | 15 | 31.29±8.96** |
| 4 | 20 | 40.26±12.05** |
Note: compare with matched group, * P < 0.01; * P < 0.001.
5. experiment conclusion
Green and the cough with asthma sheet of the present invention can suppress U251 cell proliferation, reduces the Growth of Cells number of U251 cell, and this effect is dose dependent.
Claims (2)
1. green and cough with asthma sheet suppresses the application in DBT cell U251 cell proliferation in preparation, described green and cough with asthma sheet is made up as crude drug of little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, it is characterized in that, described green and cough with asthma sheet preparation method comprises the steps: to take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO2In supercritical extraction device, ethanol is as entrainer, and it is 4-6%, extracting pressure 15-30MPa that entrainer accounts for the percent by volume of total extractant, temperature 30-50 DEG C, CO2Flow l-3ml/g crude drug min, extraction time 700-800min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
2. the green and cough with asthma sheet according to claim l suppresses the application in DBT cell U251 cell proliferation in preparation, it is characterized in that, described green and cough with asthma sheet preparation method comprises the steps: to take little green splendid achnatherum 200g, fevervine 200g, Caulis Mahoniae 100g, Caulis Marsdeniae Tenacissimae 100g, Pseudobulbus Bletillae (Rhizoma Bletillae) 100g, Rhizoma Polygoni Cuspidati 100g, Herba speranskiae tuberculatae 100g, Rhizoma Polygonati 100g, joins CO2In supercritical extraction device, ethanol is as entrainer, and it is 5% that entrainer accounts for the percent by volume of total extractant, extracting pressure 25MPa, temperature 40 DEG C, CO2Flow 2ml/g crude drug min, extraction time 750min, obtain supercritical extract, supercritical extract added starch, 70% ethanol granule, dry, and tabletting makes 200, every tablet weight 0.50g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610088723.0A CN105663715A (en) | 2016-02-17 | 2016-02-17 | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610088723.0A CN105663715A (en) | 2016-02-17 | 2016-02-17 | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105663715A true CN105663715A (en) | 2016-06-15 |
Family
ID=56304443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610088723.0A Withdrawn CN105663715A (en) | 2016-02-17 | 2016-02-17 | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105663715A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494878A (en) * | 2013-10-08 | 2014-01-08 | 南京正亮医药科技有限公司 | Preparation method and application of compound danshen tablets |
-
2016
- 2016-02-17 CN CN201610088723.0A patent/CN105663715A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494878A (en) * | 2013-10-08 | 2014-01-08 | 南京正亮医药科技有限公司 | Preparation method and application of compound danshen tablets |
Non-Patent Citations (2)
| Title |
|---|
| 凌汶静: "常用抗肿瘤中药的临床应用与规律探", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 国家药品监督管理局: "《国家中成药标准汇编内科肺系（二）分册》", 1 December 2002 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535515A (en) | Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of prostate cancer cells PC-3 | |
| CN105687726A (en) | Application of Bulbophyllum calodictyon Schlecht.cough-asthma tablets to preparation of medicine for inhibiting proliferation of breast duct cancer cells T47D | |
| CN105726961A (en) | Application of pseudobulb-of-corymbose-coelogyne cough and asthma tablets to preparation of medicine for restraining well-differentiated nasopharyngeal carcinoma cell CNE-1 multiplication | |
| CN105770025A (en) | Application of lawn pennywort herb liver healing tablet in preparation of medicine for inhibiting proliferation of breast ductal carcinoma cells T47D | |
| CN105816536A (en) | Application of lawn pennywort herb liver-healing tablets in preparation of drug for inhibiting cell proliferation of cerebral tumor cells SF767 | |
| CN105663715A (en) | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of astrocytoma cells U251 | |
| CN105663718A (en) | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of glioma cells SHG-44 | |
| CN105663719A (en) | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of histocyte lymphoma cells U937 | |
| CN105663716A (en) | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of leukemia cells K562 | |
| CN105663717A (en) | Application of cough and asthma treating Bulbophyllum calodictyon Schlecht tablets in preparation of medicine for inhibiting proliferation of kidney cancer cells ACHN | |
| CN105641447A (en) | Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of human bladder transitional cell carcinoma cells T-24 | |
| CN105641446A (en) | Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of human tongue cancer cells TCA 8113 | |
| CN105641448A (en) | Application of antitussive and antiasthmatic tablets containing bulbophyllum in preparation of drugs for inhibiting proliferation of cervical cancer cells U14 | |
| CN105687728A (en) | Application of antitussive and antiasthmatic tablets containing Bulbophyllum calodictyon to preparation of drugs for inhibiting SCaBER cell proliferation | |
| CN105343292A (en) | Application of hance brandisia herb tablets in preparation of drugs for inhibiting endometrial carcinoma cell HEC-1B proliferation | |
| CN105687727A (en) | Application of Bulbophyllum calodictyon Schlecht.cough-asthma tablets to preparation of medicine for inhibiting proliferation of small intestine cancer cells HIC | |
| CN105616996A (en) | Application of bulbophyllum and rhizoma bletillae cough and asthma tablets to preparing embryoma cell F9 proliferation suppressing medicines | |
| CN105616995A (en) | Application of bulbophyllum and rhizoma bletillae cough and asthma tablets to preparing uterine high-differentiation squamous cancer cell HCC (hepatic cellular cancer) proliferation suppressing medicines | |
| CN105521297A (en) | Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human ileocecal carcinoma cells HCT-8 | |
| CN105521298A (en) | Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human oral epidermoid carcinoma cells KB | |
| CN105521296A (en) | Application of cough and asthma treating tablet containing seudobulb of corymbose coelogyne in preparing medicine for inhibiting cell proliferation of human choriocarcinoma cells JAR | |
| CN105535514A (en) | Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of lung adenocarcinma cells H1299 | |
| CN105687643A (en) | Application of Yiganle tablets in preparing medicine for inhibiting cell proliferation of ileocecum adenocarcinoma cell HCT-8 | |
| CN105687641A (en) | Application of Yiganle tablets in preparing medicine for inhibiting cell proliferation of malignant pleural mesothelioma cell SMC-1 | |
| CN105687642A (en) | Application of Yiganle tablets in preparing medicine for inhibiting cell proliferation of lung adenocarcinoma cell SPC-A-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160615 |